AGO3

Across TCGA pan-cancer cohorts, AGO3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated AGO3 data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher AGO3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated AGO3 expression acts as an unfavorable survival marker.

UCEC, LUAD, and PDAC are the cancer types where AGO3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Median	III,IV	0.311	1.000	.001	24	view →
LUAD	DFS	Median	II,III,IV	0.674	0.964	.002	20	view →
PDAC	OS	Median	III,IV	0.601	0.878	.005	14	view →
COAD	DFS	Median	III,IV	0.835	1.000	.033	12	view →
LSCC	DFS	Tertile	All	0.641	0.872	.028	7	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

AGO3–UCEC (OS)

Open the UCEC breakdown →